<DOC>
	<DOC>NCT02335606</DOC>
	<brief_summary>Abatacept Registry in Taiwan</brief_summary>
	<brief_title>Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com ≥ 20 years of age Who give informed consent Confirmed diagnosis of RA (as defined by American College of Rheumatology revised 1987 criteria) and has ≥ 4 of the criteria listed below for ≥6 weeks before study enrollment Who selfpay or who are reimbursed by BNHI for abatacept treatment With latent TB or who are receiving antiTB treatment (INH 300 mg, QD) 1 month prior to using abatacept and continuously up to a total of 9 months Willing to follow Taiwan Risk Management Plan guidelines as required by Taiwan health authorities Are being treated with abatacept or are abatacept treatment naïve and are initiating abatacept therapy Pregnant or breast feeding With active TB HBsAg (+)and/or AntiHCV(+) and/or HBV DNA(+) Have cancer (patients who were treated and have no sign of cancer for &gt; 10 years can be included) Are allergic to abatacept Enrolled in other RA clinical studies</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>